サンプル依頼リスト カート
  • English
  • Korean
表紙：塩酸フェニレフリンの世界市場-2023年～2030年
市場調査レポート
商品コード
1374845

塩酸フェニレフリンの世界市場-2023年～2030年

Global Phenylephrine Hydrochloride Market - 2023-2030

出版日
ページ情報
英文 189 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
塩酸フェニレフリンの世界市場-2023年～2030年
出版日: 2023年11月01日
発行: DataM Intelligence
ページ情報: 英文 189 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

塩酸フェニレフリンは、アドレナリンおよびエフェドリンと化学的に関連し、強力な血管収縮作用および鬱血除去作用を有する直接作用型交感神経作動性アミンであるフェニレフリンの塩形態です。フェニレフリンは、シナプス後α-アドレナリン受容体アゴニストであり、血管収縮、収縮期/拡張期圧の上昇、反射性徐脈、および脳卒中出力を増加させる。特に風邪、アレルギー性鼻炎、副鼻腔炎の治療に用いられます。

さらに、塩酸フェニレフリンは錠剤、カプセル剤、注射剤、点鼻薬、点眼薬の形で入手可能です。塩酸フェニレフリンは、風邪やアレルギーのような症状によって引き起こされる鼻づまりを緩和するために、鼻の充血除去剤製品によく使用されます。また、副鼻腔のうっ血や圧迫感を和らげるためにも使用されます。症状を和らげますが、症状の原因を治療したり、回復を早めたりすることはありません。鼻や副鼻腔の血管を細くし、呼吸を楽にします。また、一部の眼疾患の治療にも使用されます。

市場力学：促進要因

鼻の不快感と眼障害の緩和を目的とした採用の増加

鼻の不快感を緩和するための採用が増加しており、予測期間にわたって市場を牽引すると見込まれます。風邪、アレルギー、呼吸器感染症など、鼻の不快感につながる症状の発生率の増加は、塩酸フェニレフリンの需要を促進し、これも採用の増加につながると予想されます。目の疾患は最も一般的であり、散瞳などの目の疾患を緩和するために、塩酸フェニレフリンスプレーが一般的に採用されています。

例えば、2023年8月3日、散瞳用のMydcombi（トロピカミドおよび塩酸フェニレフリン点眼液）1%/2.5%を商業化している眼科技術企業であるEyenovia, Inc.は、Mydcombiの最初の商業販売をクリアしました。Mydcombiは米国食品医薬品局から承認されました。

さらに、塩酸フェニレフリン製剤は一般用医薬品（OTC）として販売されており、消費者は処方箋を必要とせずに鼻の不快感を自己治療する傾向が強く、採用拡大に寄与している可能性があります。便利な点鼻薬、点眼薬、眼科用スプレー、複数の症状に対応する配合剤など、革新的な製剤のイントロダクションは、より多くの消費者を惹きつける可能性があります。

例えば、2022年11月15日、キンダーファーマシューティカルカンパニーのキンダーファームは、臨床的に証明された有効成分を使用しながらも、クリーンなキンダー非活性成分を使用した、クリーンな子供用医薬品のラインであるキンダーメッドを発売しました。今回の発売には、「キッズ夜用かぜ・せき」（塩酸ジフェンヒドラミン、塩酸フェニレフリン）が含まれます。キンダーメッドは全国19,000以上の店舗で発売されました。

さらに、採用の増加により、より高度な塩酸フェニレフリン製剤の開発にますます注目が集まっています。例えば、2020年6月12日、Caplin Point Laboratories Limitedは、塩酸フェニレフリン注射液USP、10mg/mL単回用量バイアル、50mg/5mL（10mg/mL）薬局用バルクパッケージ、100mg/10mL（10mg/mL）薬局用バルクパッケージの簡略新薬承認申請（ANDA）を米国食品医薬品局（USFDA）から最終承認されました。

さらに、アレルギー性疾患、眼科疾患、鼻疾患、低血圧の有病率の増加、FDA承認の増加、臨床試験の増加、塩酸フェニレフリンの利点に関する認知度の増加、製品開拓の進展などが、予測期間中に市場を牽引すると予想される要因です。

阻害要因

軽度の胃のむかつき、睡眠障害、めまい、ふらつき、頭痛、神経過敏、震え、速い心拍など、塩酸フェニレフリンに関連する合併症や副作用のような要因や、この製品は手や足の血流を低下させる可能性もあり、市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 鼻の不快感と目疾患の緩和を目的とした採用の増加
    • 抑制要因
      • 塩酸フェニレフリンに伴う副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • アンメットニーズ
  • 特許分析
  • ボリューム分析
  • DMIのオピニオン

第6章 COVID-19分析

第7章 タイプ別

  • (R) - (-) 塩酸フェニレフリン
  • L (-) - 塩酸フェニレフリン
  • その他

第8章 用途別

  • 呼吸器疾患
  • 眼科疾患
  • アレルギー性疾患
  • その他

第9章 投与経路別

  • 経口
  • 経鼻
  • 静脈注射
  • 眼科
  • その他

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Thermo Fisher Scientific Inc.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Hikma Pharmaceuticals PLC
  • Fresenius Kabi USA
  • Pfizer Inc.
  • FUJIFILM Wako Pure Chemical Corporation
  • Merck KGaA
  • Sagent Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Inc.
  • Ralington Pharma LLP
  • GRIFFITH OVERSEAS PVT. LTD.

第14章 付録

目次
Product Code: PH7393

Overview

Phenylephrine hydrochloride is the salt form of phenylephrine, a direct-acting sympathomimetic amine chemically related to adrenaline and ephedrine with potent vasoconstrictor and decongestant properties. Phenylephrine is a post-synaptic alpha-adrenergic receptor agonist that causes vasoconstriction, increases systolic/diastolic pressures, reflex bradycardia, and stroke output. It is especially used for the treatment of colds, allergic rhinitis and sinusitis.

Moreover, phenylephrine hydrochloride is available in the form of tablets, capsules, injections, nasal sprays and eye drops. Phenylephrine hydrochloride is often used in nasal decongestant products to relieve congestion caused by conditions like the common cold or allergies. It is also used to relieve sinus congestion and pressure. It will relieve symptoms but will not treat the cause of the symptoms or speed recovery. It reduces the size of the blood vessels in the nose and sinuses helping to breathe more easily. It is also used to treat some eye disorders.

Market Dynamics: Drivers

Increasing adoption to alleviate nasal discomfort and eye disorders

The increasing adoption to alleviate nasal discomfort is expected to drive the market over the forecast period. The growing incidence of conditions that are leading to nasal discomforts, such as the common cold, allergies, or respiratory infections is expected to drive the demand for phenylephrine hydrochloride and this also leads to increasing adoption. Eye disorders are most common, and to get relief from eye disorders such as mydriasis, phenylephrine HCL sprays are commonly adopted.

For instance, on August 03, 2023, Eyenovia, Inc., an ophthalmic technology company commercializing Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis, cleared the first commercial sale of Mydcombi. Mydcombi was approved by the US Food and Drug Administration.

Moreover, phenylephrine hydrochloride products are available over-the-counter (OTC), and consumers may be more inclined to self-treat nasal discomfort without the need for a prescription, contributing to increased adoption. The introduction of innovative formulations, such as convenient nasal sprays, eye drops and ophthalmic spray applications or combination products addressing multiple symptoms, may attract more consumers.

For instance, on November 15, 2022, KinderFarms, the Kinder Farmaceutical Company launched KinderMed, a line of clean children's medicines, made with clinically proven active ingredients, but clean, Kinder inactive ingredients. This launch includes Kids' Nighttime Cold and Cough (Diphenhydramine HCl, Phenylephrine HCl). KinderMed launched at over 19,000 stores nationwide.

In Addition, the increasing adoption leads to an increasing focus on developing more advanced phenylephrine hydrochloride products. For instance, on June 12, 2020, Caplin Point Laboratories Limited cleared the granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Phenylephrine Hydrochloride injection USP, 10 mg/mL Single-Dose Vial, 50 mg/5 mL (10mg/mL) Pharmacy Bulk Package, and 100 mg/10 mL (10 mg/mL) Pharmacy Bulk Package, a generic therapeutic equivalent version of (RLD), VAZCULEP Injection.

Further, the increasing prevalence of allergic, ophthalmic, nasal disorders and hypotension, rising FDA approvals, increasing clinical trials, increasing awareness about the advantages of phenylephrine hydrochloride and advancements in the development of products are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications and side effects associated with the phenylephrine hydrochloride such as mild upset stomach, trouble sleeping, dizziness, lightheadedness, headache, nervousness, shaking, or fast heartbeat and this product may also reduce blood flow to hands or feet are expected to hamper the market.

Segment Analysis

The global phenylephrine hydrochloride market is segmented based on type, application, route of administration, distribution channel and region.

The ®-(-)-phenylephrine hydrochloride segment accounted for approximately 48.5% of the phenylephrine hydrochloride market share

The ®-(-)-phenylephrine hydrochloride segment is expected to hold the largest market share over the forecast period. ®-(-)-Phenylephrine hydrochloride is a phenylephrine and an α1-adrenoceptor agonist that promotes hypertrophic growth in the ventricular myocytes and activates several MAPK signaling pathways. ®-(-)-Phenylephrine hydrochloride is an activator of α1A-AR, α1D-AR and α1B-AR.

Moreover, ®-(-)-Phenylephrine HCL is known to be more selective for alpha-adrenergic receptors. This selectivity can enhance its effectiveness in targeting specific receptors responsible for vasoconstriction and nasal decongestion. The ®-(-)-enantiomer is very well known for its fewer side effects. This can contribute to a better safety profile for individuals using medications containing phenylephrine hydrochloride.

Additionally, ®-(-)-Phenylephrine hydrochloride may have become an industry standard for pharmaceutical formulations designed to alleviate nasal congestion. With this increasing adoption due to their advantages, the demand for ®-(-)-Phenylephrine hydrochloride is continuously increasing.

Geographical Analysis

North America accounted for approximately 39.6% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and advanced healthcare facilities. North America especially the United States is home to the presence of major players such as pharmaceutical companies which are focussing on developing the major phenylephrine hydrochloride products.

For instance, on May 21, 2021, Ritedose, launched two new unit dose syringe products, Phenylephrine Hydrochloride Injection 0.8 mg/10 mL (80 mcg/mL) and Phenylephrine Hydrochloride Injection 1 mg/10 mL (100 mcg/mL). These are part of a six-month, 12-product rollout from Ritedose for hospital pharmacies across the country.

Furthermore, the well-established healthcare infrastructure in the region, including pharmacies, clinics, and hospitals, facilitates the distribution and accessibility of these products. Phenylephrine hydrochloride is commonly available as an over-the-counter (OTC) medication. The accessibility of OTC products can contribute to a higher market share as consumers may purchase them without a prescription.

Competitive Landscape

The major global players in the phenylephrine hydrochloride market include: Thermo Fisher Scientific Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi USA, Pfizer Inc., FUJIFILM Wako Pure Chemical Corporation, Merck KGaA, Sagent Pharmaceuticals, Inc., Dr. Reddy's Laboratories Inc., Ralington Pharma LLP and GRIFFITH OVERSEAS PVT. LTD. Among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global phenylephrine hydrochloride market. During the pandemic, healthcare systems globally focused on managing and treating COVID-19 cases. This shift in priorities impacted the demand for certain non-essential pharmaceuticals, including phenylephrine hydrochloride products like decongestants. The pandemic impacted the market by temporarily disrupting many clinical trials and research activities due to the redirected focus on the COVID-19 pandemic. The pandemic also disrupted the supply chain of these products globally.

Market Segmentation

By Type

  • ®-(-)-Phenylephrine Hydrochloride
  • L(-)-Phenylephrine Hydrochloride
  • Others

By Application

  • Respiratory Disorders
  • Ophthalmic Disorders
  • Allergic Disorders
  • Others

By Route of Administration

  • Oral
  • Nasal
  • Intravenous
  • Ophthalmic
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Why Purchase the Report?

  • To visualize the global phenylephrine hydrochloride market segmentation based on type, application, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of phenylephrine hydrochloride market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global phenylephrine hydrochloride market report would provide approximately 69 tables, 70 figures, and 189 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption to Alleviate Nasal Discomfort and Eye Disorders
    • 4.1.2. Restraints
      • 4.1.2.1. Side Effects Associated with Phenylephrine Hydrochloride
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. Patent Analysis
  • 5.8. Volume Analysis
  • 5.9. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. (R)-(-)-Phenylephrine Hydrochloride*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. L(-)-Phenylephrine Hydrochloride
  • 7.4. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Respiratory Disorders*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ophthalmic Disorders
  • 8.4. Allergic Disorders
  • 8.5. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Nasal
  • 9.4. Intravenous
  • 9.5. Ophthalmic
  • 9.6. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Thermo Fisher Scientific Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Hikma Pharmaceuticals PLC
  • 13.3. Fresenius Kabi USA
  • 13.4. Pfizer Inc.
  • 13.5. FUJIFILM Wako Pure Chemical Corporation
  • 13.6. Merck KGaA
  • 13.7. Sagent Pharmaceuticals, Inc.
  • 13.8. Dr. Reddy's Laboratories Inc.
  • 13.9. Ralington Pharma LLP
  • 13.10. GRIFFITH OVERSEAS PVT. LTD.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us